Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
Dec 20, 2024 · The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in …
Vertex secures two FDA wins for cystic fibrosis, both with boxed ...
5 days ago · Cystic fibrosis is a life-threatening genetic disorder that causes sticky mucus to build up in the lungs and digestive system. Credit: Iren_Geo via Shutterstock. Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF) treatments ...
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
4 days ago · Vertex is also evaluating Alyftrek in children with cystic fibrosis aged 2 to 5 years. VRTX Stock Performance Year to date, Vertex Pharmaceuticals’ shares have lost 2.3% compared with the ...
Vertex wins FDA nod for once-daily cystic fibrosis triplet
5 days ago · As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...
Vertex wins Trikafta expansion and approval for 'vanza triple' once ...
4 days ago · Vertex Pharmaceuticals Inc. notched two FDA victories on Friday for its cystic fibrosis medicines, increasing the number of patients eligible for its drugs and likely boosting its own future revenue.
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
Dec 20, 2024 · Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has approved ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis transmembrane ...
Vertex Wins FDA Approval for New Cystic Fibrosis Option but
5 days ago · Vertex Pharmaceuticals said Friday the FDA has approved its next cystic fibrosis product Alyftrek, clearing the biotech to market a product designed to improve on Trikafta.. William Blair analysts see the early approval of Alyftrek, which had a PDUFA of Jan 2., 2025, as a positive for the company’s stock, though it has yet to rebound from last week’s crash following disappointing results ...
US FDA approves Vertex Pharma's triple combo cystic fibrosis
The drugmaker, with almost $10 billion in sales last year, has significantly impacted cystic fibrosis treatment, turning it from a disease with a median death age of around 30 years to a ...
Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval
Dec 20, 2024 · (RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis. Alyftrek is a once-daily ...
News & Events - Vertex Pharmaceuticals
Jul 2, 2024 · The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in …
- Some results have been removed